產品描述: | ML355是有效的選擇性h12-LOX抑制劑,IC50為290 nM |
靶點: |
12-LOX;Lipoxygenase |
體外研究: |
ML355 displays nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases |
體內研究: |
In vivo PK studies where ML355 is administered as a solution via IV (3mpk) and PO (30mpk) demonstrated that ML355 is orally bioavailable (%F = 20) with good half-life (T1/2 = 2.9 hours). At 30 mpk dosing, ML355 achieves a Cmax of over 135 times the in vitro IC50 and remains over IC50 value for over 12 hours. The compound has low clearance (3.4 mL/min/kg) and good overall exposure (AUCinf) of 38 μM. Although, the volume of distribution (VD) observed is low (0.55 L/kg), the rest of the PK profiling results suggest a reasonable distribution between tissue and blood |
細胞實驗: |
Cell lines: U87 cells Concentrations: 10 μM Incubation Time: 24 h Method: Cells were treated with indicated concentration of drug for 24 h. |
動物實驗: |
Animal Models: C57BL/6 mice Dosages: 15 or 30 mg/kg Administration: p.o. |
參考文獻: |
1. Luci D, et al. Discovery of ML355, a Potent and Selective Inhibitor of Human 12-Lipoxygenase. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2013 Apr 12 [updated 2014 Sep 18]. 2. Yang X, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021 Feb 12;10(2):15. 3. Adili R, et al. First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1828-1839. |
溶解性: |
Soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.265 ml |
11.324 ml |
22.649 ml |
5 mM |
0.453 ml |
2.265 ml |
4.53 ml |
10 mM |
0.226 ml |
1.132 ml |
2.265 ml |
50 mM |
0.045 ml |
0.226 ml |
0.453 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |